Cargando…
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086312/ https://www.ncbi.nlm.nih.gov/pubmed/37038324 http://dx.doi.org/10.1002/prp2.1083 |
| _version_ | 1785022123652153344 |
|---|---|
| author | Rothlin, Rodolfo Pedro Pelorosso, Facundo Germán Duarte, Mariano Nicolosi, Liliana Ignacio, Fernandez Criado Salgado, María Victoria Vetulli, Héctor |
| author_facet | Rothlin, Rodolfo Pedro Pelorosso, Facundo Germán Duarte, Mariano Nicolosi, Liliana Ignacio, Fernandez Criado Salgado, María Victoria Vetulli, Héctor |
| author_sort | Rothlin, Rodolfo Pedro |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10086312 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100863122023-04-12 Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 Rothlin, Rodolfo Pedro Pelorosso, Facundo Germán Duarte, Mariano Nicolosi, Liliana Ignacio, Fernandez Criado Salgado, María Victoria Vetulli, Héctor Pharmacol Res Perspect Commentary John Wiley and Sons Inc. 2023-04-10 /pmc/articles/PMC10086312/ /pubmed/37038324 http://dx.doi.org/10.1002/prp2.1083 Text en © 2023 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Commentary Rothlin, Rodolfo Pedro Pelorosso, Facundo Germán Duarte, Mariano Nicolosi, Liliana Ignacio, Fernandez Criado Salgado, María Victoria Vetulli, Héctor Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 |
| title | Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 |
| title_full | Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 |
| title_fullStr | Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 |
| title_full_unstemmed | Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 |
| title_short | Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19 |
| title_sort | telmisartan and losartan: the marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with covid‐19 |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086312/ https://www.ncbi.nlm.nih.gov/pubmed/37038324 http://dx.doi.org/10.1002/prp2.1083 |
| work_keys_str_mv | AT rothlinrodolfopedro telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 AT pelorossofacundogerman telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 AT duartemariano telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 AT nicolosililiana telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 AT ignaciofernandezcriado telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 AT salgadomariavictoria telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 AT vetullihector telmisartanandlosartanthemarkeddifferencesbetweentheirchemicalandpharmacologicalpropertiesmayexplainthedifferenceintherapeuticefficacyinhospitalizedpatientswithcovid19 |